

1 Functionalized microcarriers improve T cell manufacturing by facilitating 2 migratory memory T cell production and increasing CD4/CD8 ratio

3 Nathan J. Dwarshuis¹, Hannah W. Song¹, Anokhi Patel¹, Theresa Kotanchek², and Krishnendu Roy¹

4 ¹Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and
5 Emory School of Medicine, Atlanta, GA

6 ²Evolved Analytics LLC, Midland, MI

7 **Abstract**

8 Adoptive cell therapies (ACT) using chimeric antigen receptor (CAR) T cells have shown promise in treating
9 cancer, but manufacturing large numbers of high quality cells remains challenging. Critically, current T cell ex-
10 pansion technologies only partially recapitulate the *in vivo* microenvironment found in the human lymph nodes.
11 In these organs, T cells expand at high cell density with autocrine/paracrine signaling, as well as signals from
12 the extracellular matrix (ECM). Here we describe a T cell expansion system using degradable gelatin microcar-
13 riers functionalized with anti-CD3 and anti-CD28 monoclonal antibodies (mAbs), which address several of these
14 shortcomings. We show that using this system, we can achieve approximately 2-fold greater expansion compared
15 to functionalized magnetic beads, the current industry standard. Furthermore, carriers generated higher numbers
16 of CCR7+CD62L+ migratory, central memory T cells and CD4+ T cells across multiple donors. Both these
17 phenotypes have emerged as important for establishing durable and effective responses in patients receiving T
18 cell immunotherapies. We further demonstrate that carriers can achieve greater memory cell yield compared to
19 beads across a range of IL2 concentrations from 20 U/mL to 100 U/mL. These differences were greater at lower
20 IL2 concentrations, indicating that the carriers are more efficient. We optimized this system using a design of
21 experiments (DOE) approach and found that the carrier concentration affects the memory cell yield in a quadratic
22 manner, where high or low concentrations are detrimental to memory formation. Finally, we show that carriers do
23 not hinder CAR transduction and can maintain the CD4 and memory phenotype advantages in CAR-transduced
24 T cells.

25 **Introduction**

26 T cell-based immunotherapies have received great interest from clinicians and industry due to their potential to treat,
27 and often finally cure, cancer and other diseases [1, 2]. In 2017, Novartis and Kite Pharma acquired FDA approval

28 for *Kymriah* and *Yescarta* respectively, two genetically-modified CAR T cell therapies against B cell malignancies.
29 Despite these successes, CAR T cell therapies are constrained by an expensive and difficult-to-scale manufacturing
30 process [3, 4].

31 State-of-the-art manufacturing techniques focus only on anti-CD3 and anti-CD28 activation, typically presented
32 on a microbead (Invitrogen Dynabead, Miltenyi MACS beads) or nanobead (Miltenyi TransACT), but also in soluble
33 forms in the case of antibody tetramers (Expamer) [3, 5–7]. These strategies overlook many of the signaling com-
34 ponents present in the secondary lymphoid organs where T cells normally expand. Typically, T cells are activated
35 under close cell-cell contact via antigen presenting cells (APCs) such as dendritic cells (DCs), which present peptide-
36 major histocompatibility complexes (MHCs) to T cells as well as a variety of other costimulatory signals. These close
37 quarters allow for efficient autocrine/paracrine signaling among the expanding T cells, which secrete IL2 and other
38 cytokines to assist their own growth. Additionally, the lymphoid tissues are comprised of ECM components such as
39 collagen, which provide signals to upregulate proliferation, cytokine production, and pro-survival pathways [8–11].

40 A variety of solutions have been proposed to make the T cell expansion process more physiological. One strategy
41 is to use modified feeder cell cultures to provide activation signals similar to those of DCs [12]. While this has the
42 theoretical capacity to mimic many components of the lymph node, it is hard to reproduce on a large scale due to
43 the complexity and inherent variability of using cell lines in a fully Good Manufacturing Practices (GMP)-compliant
44 manner. Others have proposed biomaterials-based solutions to circumvent this problem, including lipid-coated mi-
45 crorods [13], 3D-scaffolds via either Matrigel [14] or 3d-printed lattices [15], ellipsoid beads [16], and mAb-conjugated
46 polydimethylsiloxane (PDMS) beads [17] that respectively recapitulate the cellular membrane, large interfacial con-
47 tact area, 3D-structure, or soft surfaces T cells normally experience *in vivo*. While these have been shown to provide
48 superior expansion compared to traditional microbeads, no method has been able to show preferential expansion of
49 functional memory and CD4 T cell populations. Generally, T cells with a lower differentiation state such as memory
50 cells have been shown to provide superior anti-tumor potency, presumably due to their higher potential to replicate,
51 migrate, and engraft, leading to a long-term, durable response [18–21]. Likewise, CD4 T cells are similarly important
52 to anti-tumor potency due to their cytokine release properties and ability to resist exhaustion [22, 23]. Therefore,
53 methods to increase memory and CD4 T cells in the final product are needed, a critical consideration being ease of
54 translation to industry and ability to interface with scalable systems such as bioreactors.

55 Here we describe a method using porous microcarriers functionalized with anti-CD3 and anti-CD28 mAbs for
56 use in T cell expansion cultures. Microcarriers have historically been used throughout the bioprocess industry for
57 adherent cultures such as stem cells and Chinese hamster ovary (CHO) cells, but not with suspension cells such as
58 T cells [24, 25]. The carriers used in this study have a macroporous structure that allows T cells to grow inside and
59 along the surface, providing ample cell-cell contact for enhanced autocrine and paracrine signaling. Furthermore,
60 the carriers are composed of gelatin, which is a collagen derivative and therefore has adhesion domains that are also
61 present within the lymph nodes. Finally, the 3D surface of the carriers provides a larger contact area for T cells to

62 interact with the mAbs relative to beads; this may better emulate the large contact surface area that occurs between
63 T cells and DCs. We show that compared to traditional beads, carrier-expanded T cells not only provide superior
64 expansion, but consistently provide a higher frequency of memory and CD4 T cells (CCR7+CD62L+) across multiple
65 donors. We also demonstrate functional cytotoxicity using a CD19 CAR. Our results indicate that functionalized
66 microcarriers provide a robust and scalable platform for manufacturing therapeutic T cells with higher memory
67 phenotype and CD4+ cell content.

68 Results

69 Microcarriers can provide greater expansion potential compared to beads

70 Two types of carriers, Cultispher-S (CuS) and Cultispher-G (CuG), were covalently conjugated with varying concen-
71 tration of sulfo-NHS-biotin (SNB) and then coated with streptavidin (STP) (Figs. 1a and 1b). We chose to continue
72 with the CuS carriers, which showed higher overall STP binding compared to CuG. We further set the amount
73 of SNB to the lowest concentration per mass of carriers (5 M/g) that achieved maximal STP binding. We further
74 verified that the carriers had active biotin binding sites at this concentration (Fig. 1c), and demonstrated that they
75 were evenly coated throughout their interior using FITC-biotin (Fig. 1d). Finally, we confirmed that biotinylated
76 mAbs were bound to the carriers by staining either STP or mAb-coated carriers with anti-mouse immunoglobulin G
77 (IgG)-FITC and imaging on a confocal microscope (Fig. 1e).

78 We next sought to determine how our functionalized carriers could expand T cells compared to state-of-the-art
79 methods used in industry. We compared the carriers alongside traditional microbeads (Miltenyi-Biotec) by expanding
80 T cells for 14 d with several different seeding densities in the carrier cultures (Fig. 1f). All bead expansions were
81 performed as per the manufacturer's protocol. We observed a higher fold change in the carrier cultures with an
82 intermediate density of 3×10^5 cells/mL, implying that carriers could be used to achieve greater expansion than
83 conventional beads (Fig. 1g). We also observed no T cell expansion using carriers coated with an isotype control
84 mAb compared to carriers coated with anti-CD3/anti-CD28 mAbs (Fig. 1h), confirming specificity of the expansion
85 method.

86 We also asked how many cells were inside the carriers vs. free-floating in suspension and/or loosely attached to
87 the surface. After seeding carriers at different densities and expanding for 14 d, we filtered the carriers out of the
88 cell suspension and digested them using dispase to free any cells attached on the inner surface. We observed that
89 15% of the total cells on day 14 were on the interior surface of the carriers (Fig. S1a), and this did not significantly
90 change with initial seeding density (Table S1). We qualitatively verified the presence of cells inside the carriers using
91 an 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) stain to opaquely mark cells and enable
92 visualization on a brightfield microscope (Fig. S1b).




Figure 1: Functionalized carriers can expand T cells. a) Overview of the carrier coating process. b) Mass of bound STP vs. amount of SNB for CuS and CuG. c) Number of STP binding sites (defined using FITC-biotin) vs. amount of SNB used to biotinylate the CuS carriers. d) Lightsheet image of uncoated or STP-coated carriers stained with FITC-biotin. e) Confocal image of STP or mAb-coated carriers stained with anti-mouse IgG-FITC. f) Phase image of T cells expanded on carriers after 9 d. g) T cells expanded using either beads or carriers with three initial cell densities for 14 d. h) T cells expanded using either carriers coated with anti-CD3/anti-CD28 mAbs or isotype control. Abbreviations: streptavidin (STP); Cultispher-S (CuS); Cultispher-G (CuG); sulfo-NHS-biotin (SNB)

93 **Microcarriers produce higher frequencies of memory T cells and CD4+ T cells compared to conventional microbeads**
94

95 After observing differences in expansion, we further hypothesized that the carrier cultures could lead to a different
96 T cell phenotype. In particular, we were interested in the formation of memory T cells, as these represent a subset
97 with higher replicative potential and therefore improved clinical prognosis [20, 21]. We measured memory T cell
98 frequency staining for CCR7 and CD62L (both of which are present on lower differentiated T cells such as central
99 memory cells and stem memory cells [19]). After expanding T cells for 14 days using either beads or carriers, we
100 noted a distinctly larger frequency of memory T cells (CD62L+CCR7+) in the carrier cultures compared to the bead
101 cultures (Fig. 2a).




Figure 2: Carriers selectively expand memory T cell relative to beads across multiple donors and experiments. Note that Donors 1, 3, and 4 were CAR-transduced, and Donors 3, 4, and 5 were peripheral blood mononuclear cells (PBMCs) sorted through a magnetic activated cell sorting (MACS) column. a) Representative flow plots from three donors of memory T cells expanded for 14 d. b) Representative flow plots from three donors of CD4+ T cells expanded after 14 d. c) Fraction of memory cells obtained after 14 d for multiple donors across multiple experiments. d) T cell chemotaxis measured after 14 d expansion using a transwell with a CCL21 gradient

102 Of additional interest to us was the preservation of the CD4 compartment. In healthy donor samples (such as
103 those used here), the typical CD4:CD8 ratio is 2:1. We noted that carriers produced a more balanced culture with
104 CD4 T cells at a higher frequency compared to bead cultures, which had nearly 90% CD8 T cells (Fig. 2b). While
105 both systems had a preference for expanding CD8 T cells, our results indicated that the carriers allow a better
106 CD4:CD8 ratio.

107 To test if this observation was consistent across experimental conditions, we pooled data for multiple T cells
108 expansions where these markers were measured on day 14; these experiments had varying conditions as well as
109 different donors (Table S7), and thus the pooled dataset provided a test for robustness. Comparing beads and
110 carriers for both memory and CD4 T cell percentage, we noted that carriers provided a higher percentage in nearly
111 every case (Fig. 2c). This trend was similar for both memory CD4+ and CD8+ subpopulations.

112 We analyzed this pooled dataset using linear regression analysis to determine if there was a significant difference
113 between the beads and carriers in either memory or CD4 phenotype (Tables S2 and S3 and Figs. S2a and S2b). In
114 both cases, the activation method (carrier vs. bead) was highly significant, with the carriers producing 13% and
115 21% greater frequencies of memory and CD4+ T cells respectively. The regression analysis also revealed that both
116 phenotypes depended highly on donor but not on any of the aggregate process parameters (total IL2, total added
117 glucose as calculated by the amount of media added, and the fold change of culture volume increase).

118 We also verified that expanded T cells were migratory using a chemotaxis assay for CCL21; since carriers produced
119 a larger percentage of memory T cells (which have CCR7, the receptor for CCL21) we would expect higher migration
120 in carrier-expanded cells vs. their bead counterparts. Indeed, we noted a significantly higher percentage of migration
121 in carriers and a dose-dependent response to CCL21 (Figs. 2d and S3 and Table S6).

122 **Microcarriers require less IL2 for robust expansion compared to beads**

123 We next asked if T cells required less exogenous IL2 in the carriers vs. traditional beads, as the initial hypothesis
124 for the design was that the macroporous structure would allow more efficient autocrine and paracrine signaling by
125 increasing local cell density. We expanded T cells using either beads or carriers for 14 d using varying amounts of
126 IL2 from 0 U/mL to 100 U/mL added every two days. Overall, we noted that the carriers expanded the T cells more
127 robustly (Fig. 3a) and required lower IL2 concentrations while maintaining equivalent expansion (Fig. 3b). When
128 comparing the robustness of memory cell production, the carriers also produced more cells with less IL2 (Fig. 3c).
129 Furthermore, the frequency of memory T cells was greater at lower IL2 concentrations in the carrier-expanded
130 population than that of the beads (Fig. 3c).

131 **Microcarriers can be optimized to provide superior memory and CD4 T cell yield**

132 Given that less IL2 was required to expand T cells using the carriers, we sought to optimize the yield of both memory
133 T cells and CD4+ T cells at lower IL2 concentrations. To accomplish this, we employed a design of experiments




Figure 3: Carriers produce more T cells with less IL2 compared to beads. a) Growth curves of T cells expanded with either beads or carriers grown with varying concentration of IL2. b) Final fold change of T cells grown at varying IL2 concentrations with hyperbolas fitted to plots. c) Final fold change of memory T cells grown at varying IL2 concentration with hyperbolas fitted to plots. d) Flow plots of CD62L+CCR7+ T cells at each IL2 concentration for beads and carriers.

134 (DOE) methodology, a technique commonly used to optimize complex manufacturing processes. We varied the IL2
 135 concentration, the number of carriers, and the number of mAbs on the surface of the carriers. Since we desired to
 136 understand non-linear influence of these variables, we chose three levels for each (10, 20 and 30 U/mL for IL2; 500,
 137 1500 and 2500 carriers/mL for carrier concentration; 60, 80 and 100 % surface coverage for mAb surface density). Note
 138 that in the case of carrier concentration, total cell number was fixed at 2.5×10^6 cells/mL, thus this corresponded to
 139 seeding densities of 1000, 1666 and 5000 cells/carrier. This led to a randomized 18-run design which included several
 140 replicated runs to assess for lack-of-fit (Table S8). T cells were expanded for 14 d using these conditions to modify
 141 the expansion process used before.

142 While there was a wide range of fold changes across all input parameters (Fig. 4a), all runs appeared to generate
 143 cells that were greater than 90 % viable when measured using acridine orange/propidium iodide (AO/PI) stain




Figure 4: Carriers robustly expand at low IL2 concentrations and have optimal carrier and signal strength inputs. a.) Growth curve of carrier expanded cells. b.) Viability of carrier expanded cells. c.) Main effects plot for memory T cell response. d.) Main effects plot for CD4+ T cell response. e.) Interaction plots for the DOE with total CCR7+CD62L+ cells as the response.

Abbreviations: design of experiments (DOE).

Table 1: Linear regression output of the DOE experiment for the memory and CD4 T cell yield.

	Memory Cells	CD4+ Cells
Intercept	2,795,410.000	-2,375,290.000***
IL2 Conc.	785,470.300***	93,714.670***
Carrier Conc.	16,050.750***	1,528.302***
Ab Density	-24,744.790**	1,335.737***
(Ab Density) ²	10.549***	
(Carrier Conc.) ²	-2.584**	
(Ab Dens.)*(Carr. Conc.)	-1.536	
(IL2 Conc.)*(Carr. Conc.)	-249.904***	
R ²	0.897	0.858
Adjusted R ²	0.826	0.827
<i>Note:</i>	*p<0.1; **p<0.05; ***p<0.01	

144 (Fig. 4b). We additionally assessed the percentage of memory and CD4 phenotypes and plotted the number of cells
 145 with these markers at day 14. In the case of memory cell yield, IL2 appeared to be highly influential as a main effect,
 146 and the other two parameters (carrier concentration and mAb surface density) were less influential (Fig. 4c). Carrier
 147 concentration and mAb surface density appeared to have small quadratic effects. For CD4 yield, we noted that all
 148 three main effects seem to influence the number of CD4 T cells with little interaction or quadratic effects (Fig. 4d).
 149 We further investigated the presence of interaction effects in the memory cell response (Fig. 4e) and noted that there
 150 appeared to be interaction between IL2 and carrier concentration (e.g. the slope of one is dependent on the other).

151 To verify the presence of these qualitative observations in each plot, we produced a model using stepwise linear
 152 regression with Akaike information criteria (AIC) as the selection criteria (Table 1 and Figs. S4a and S4b). Neither of
 153 these models showed any lack of fit (Tables S9a and S9b), indicating that the generated models accurately described
 154 the relationship between the input variables and the response. For memory cell formation, we noted that all main
 155 effects were significant. Additionally, we observed significant quadratic effects for carrier concentration and mAb
 156 surface density, indicating that these might have an optimum in the middle of the range we tested. Additionally,
 157 we found a significant negative interaction effect between carrier concentration and mAb surface density, indicating
 158 that there may be antagonism between these two parameters. Using the equation from this model, we calculated
 159 the optimum settings for achieving high memory cell yield to be high IL2 (30 U/mL), mid carrier concentration
 160 (1500 carriers/mL), and high mAb surface density (approx. 2000 mAbs/ μm^2). For the CD4 response, only the main
 161 effects were found significant and all were positively correlated with CD4 cell yield. In this case the optimum settings
 162 were simply the high settings for each input (30 U/mL IL2, 2500 carriers/mL, and approx. 2000 mAbs/ μm^2).

163 We also performed non-linear symbolic regression analysis to compliment the stepwise linear regression. This was
 164 done using the DataModeler software package (Evolved Analytics LLC, Midland, MI) which evolves hundreds to
 165 thousands of models using genetic programming and selects the fittest models (those with the highest R^2 and lowest
 166 complexity as assessed using a Pareto front) and aggregates them into an ensemble. This has the advantage over




Figure 5: Symbolic regression ensemble plots as given by Evolved Analytics DataModeler. Response profiles of memory (a) and CD4+ (b) vs all three input parameters (IL2 concentration, carrier concentration, and mAb surface density) with optimal settings shown as a green dot. The grey lines are paths from a single given model in the ensemble, and the yellow envelopes represent the variation of the ensemble as a function of each parameter. c) Memory vs CD4+ yield as a function of each input parameter (colored lines, where red is low and green is high) as predicted by the model ensemble for each response. The green point is the optimal setting for memory yield.

167 linear regression of making fewer *a priori* assumptions about model form. When we fit a model ensemble to memory T
168 cell yield and computed the optimum settings, we observed that the optimal settings were similar to linear regression
169 with the exception of carrier concentration (30 U/mL, 750 carriers/mL and approx. 2000 mAbs/ μm^2) (Fig. 5a). This
170 ensemble consisted of 10 equations which showed robust fit with minimal residual correlations (Figs. S7, S8a, S9a
171 and S10a). When we performed the same analysis for CD4+ T cell yield, we obtained the exact same optimum
172 settings as given by linear regression (30 U/mL IL2, 2500 carriers/mL, and approx. 2000 mAbs/ μm^2). These likewise
173 showed good fit and minimal residual correlation (Figs. S7, S8b, S9b and S10b). Additionally, we plotted the
174 memory and CD4+ T cell yield at the optimal memory settings, and observed a trade-off of the yield between these
175 two subtypes as a function of carrier concentration (Fig. 5c). The optimum setting results from both linear and
176 symbolic regression are summarized in Table 2.

Table 2: Summary of predicted process optimums.

Response	Parameter	Linear Regression	Symbolic Regression
CCR7+CD62L+	IL2 Concentration	High	High
	Carrier Concentration	Mid	Low
	mAb Surface Density	High	High
CD4+	IL2 Concentration	High	High
	Carrier Concentration	High	High
	mAb Surface Density	High	High

177 Since the total yield of each phenotype was the product of the total cell number and the percentage of that
178 phenotype, we also asked if the total memory and CD4 T cell yields were primarily influenced by bulk T cell
179 expansion or the selective differentiation of a particular phenotype. When performing the same regression on the
180 bulk T cell expansion, memory percentage, or CD4 percentage, we noted that the total live cell response had the
181 same variables in its regression output as the memory yield, indicating that this was likely the main driver of this
182 memory yield composite response (Table S10 and Fig. S5c). However, we also noted that the percentage of memory
183 T cells was negatively affected by increasing carrier concentration (and not by any of the other two variables)
184 (Table S10 and Fig. S5a). In contrast, the CD4 percentage was positively affected by the carrier concentration and
185 the mAb surface density (Table S10 and Fig. S5b). Interestingly, IL2 concentration only affected the bulk expansion.
186 Together, these provided evidence that the differentiation and expansion of memory and CD4 cells were somehow
187 opposed in the carrier system, and the desired balance of CD4 cells and memory cells can be determined by selecting
188 the appropriate carrier concentration.

189 Microcarriers can be used to expand functional CAR T cells

190 After optimizing for memory and CD4 yield, we sought to determine if the carriers were compatible with lentiviral
191 transduction protocols used to generate CAR T cells [26,27]. We added a 24 h transduction step on day 1 of the 14 d
192 expansion to insert an anti-CD19 CAR [28] and subsequently measured the surface expression of the CAR on day

193 14 (Figs. 6a and 6b). We noted that there was robust CAR expression in over 25% of expanded T cells, and there
 194 was no observable difference in CAR expression between beads and carriers.

195 We also verified the functionality of expanded CAR T cells using a degranulation assay [29]. Briefly, T cells were
 196 cocultured with target cells (either wild-type K562 or CD19-expressing K562 cells) for 4 h, after which the culture was
 197 analyzed via flow cytometry for the appearance of CD107a on CD8+ T cells. CD107a is found on the inner-surface
 198 of cytotoxic granules and will emerge on the surface after cytotoxic T cells are activated and degranulate. Indeed,
 199 we observed degranulation in T cells expanded with both beads and carriers, although not to an observably different
 200 degree (Figs. 6c and 6d). Taken together, these results indicated that the carriers provide similar transduction
 201 efficiency compared to beads.




Figure 6: Carriers produce functional CAR T cells. a) CAR expression on day 14 as assessed via flow cytometry for protein L. b) Flow plots from (a) quantified and plotted. c) T cells at day 14 tested for cytotoxicity by measuring CD107a degranulation marker on CD8+ T cells using K562 wild-type or K562-CD19 target cells. Each data point is plotted as a difference in CD107a expression between CD19 and wild-type K562 target cell cultures. d) Flow plots for the degranulation assay shown in (c).

Discussion

We have developed a T cell expansion system that recapitulates key features of the *in vivo* lymph node microenvironment using microcarriers functionalized with activating mAbs. This strategy provided superior expansion with higher frequency of memory and CD4+ T cells compared to state-of-the-art microbead technology (Fig. 2). Other groups have used biomaterials approaches to mimic the *in vivo* microenvironment [13–15, 17, 30]; however, to our knowledge this is the first system that specifically drives memory and CD4+ T cell formation in a scalable, potentially bioreactor-compatible manufacturing process.

Memory T cells have been shown to be important clinically. Compared to effectors, they have a higher proliferative capacity and are able to engraft for months; thus they are able to provide long-term immunity with smaller doses [19, 31]. Indeed, less differentiated T cells have led to greater survival both in mouse tumor models and human patients [20, 32, 33]. Furthermore, clinical response rates have been positively correlated with T cell expansion, implying that highly-proliferative memory T cells are a significant contributor [18, 34]. Circulating memory T cells have also been found in complete responders who received CAR T cell therapy [35].

Similarly, CD4 T cells have been shown to play an important role in CAR T cell immunotherapy. It has been shown that CAR T doses with only CD4 or a mix of CD4 and CD8 T cells confer greater tumor cytotoxicity than only CD8 T cells [22, 36]. There are several possible reasons for these observations. First, CD4 T cells secrete pro-inflammatory cytokines upon stimulation which may have a synergistic effect on CD8 T cells. Second, CD4 T cells may be less prone to exhaustion and may more readily adopt a memory phenotype compared to CD8 T cells [22]. Third, CD8 T cells may be more susceptible than CD4 T cells to dual stimulation via the CAR and endogenous T Cell Receptor (TCR), which could lead to overstimulation, exhaustion, and apoptosis [23]. Despite evidence for the importance of CD4 T cells, more work is required to determine the precise ratios of CD4 and CD8 T cell subsets to be included in CAR T cell therapy given a disease state.

There are several plausible explanations for the observed phenotypic differences between beads and carriers. First, the carriers are composed of a collagen derivative (gelatin); collagen has been shown to costimulate activated T cells via $\alpha 1\beta 1$ and $\alpha 2\beta 1$ integrins, leading to enhanced proliferation, increased IFN γ production, and upregulated CD25 (IL2R α) surface expression [8, 10, 11, 37, 38]. Second, there is evidence that providing a larger contact area for T cell activation provides greater stimulation [16, 39]; the carriers have a rougher interface than the 5 μ m magnetic beads, and thus could facilitate these larger contact areas. Third, the carriers may allow the T cells to cluster more densely compared to beads, as evidenced by the large clusters on the outside of the carriers (Fig. 1f) as well as the significant fraction of carriers found within their interiors (Figs. S1a and S1b). This may alter the local cytokine environment and trigger different signaling pathways. Particularly, IL15 is secreted by T cells and known to drive memory phenotype [40–42]. The higher cell density in carrier cultures could lead to greater IL15 signaling and thus higher memory cell formation.

An important aspect to our study was the inclusion of a DOE, which is used in many other non-biological

236 disciplines for process development. We specifically used this strategy here to optimize three process variables
237 that plausibly affected T cell growth and phenotype differentiation (IL2 concentration, carrier concentration, and
238 mAb surface density). Additionally, a DOE can facilitate generation of new hypotheses that may explain the
239 potential interactions between parameters. For carrier concentration, we reasoned that this would be directly related
240 to the available surface area, and thus control the degree to which T cell cluster and aggregate. Surprisingly,
241 carrier concentration negatively affected memory cell formation but positively affected CD4 cell formation (Fig. S5
242 and Table S10). In the case of memory, IL15 is known to drive memory phenotype [40–42], thus the negative
243 relationship between memory fraction and carrier concentration could indicate that other cytokines may start to
244 dominate when the local cell density is increased. In addition to carrier concentration, we varied IL2 concentration
245 as this cytokine has long been known to be required for T cell growth. Our data showed that carriers can lead to
246 robust growth at low IL2 concentrations (20 U/mL) (Fig. 3), thus we decided to investigate this low range in further
247 detail. The DOE revealed that IL2 only affected growth and not phenotype differentiation, as IL2 did not significantly
248 affect memory or CD4 percentage (Fig. S5 and Table S10). This may be because the local IL2 concentration around
249 the carriers was high enough to lessen the effect of exogenous IL2. Furthermore, while the bulk expansion of T cells
250 was influenced by IL2, the negative interaction effect between the IL2 and carrier concentration suggested that IL2 is
251 less influential as the carrier concentration is increased and the cells are clustered more closely, further supporting the
252 hypothesis that the carriers alter the local cytokine concentration. Finally, mAb surface density positively influenced
253 both memory and CD4 T cell formation. This was surprising in the case of memory, since higher stimulation biases
254 differentiation toward effector phenotypes [43]. It could be that in our case, the higher stimulation also increased
255 cytokine output such as IL15, which in turn drove memory cell formation. Ultimately, while the DOE provided an
256 optimal set of conditions that can be used to produce higher numbers of T cells in practice, the surprising findings
257 also generated interesting hypotheses that may lead to better mechanistic understanding and further optimization.
258 These are undergoing further investigation.

259 In addition to obtaining better phenotypes, other advantages of our carrier approach are that the carriers are large
260 enough to be filtered (approximately 300 μm) using standard 40 μm cell filters or similar. If the remaining cells inside
261 that carriers are also desired, digestion with dispase or collagenase can be used. Furthermore, our system should be
262 compatible with large-scale static culture systems such as the G-Rex bioreactor or perfusion culture systems, which
263 have been previously shown to work well for T cell expansion [12, 44, 45].

264 It is important to note that all T cell cultures in this study were performed up to 14 days. Others have demon-
265 strated that potent memory T cells may be obtained simply by culturing T cells as little as 5 days using traditional
266 beads [29]. It is unknown if the memory phenotype of our carrier system could be further improved by reducing the
267 culture time, but we can hypothesize that similar results would be observed given the lower number of doublings
268 in a 5 day culture. We should also note that we investigated one memory subtype (CCR7+CD62L+) in this study.
269 Future work will focus on other memory subtypes such as tissue resident memory and stem memory T cells, as well

270 as the impact of using the microcarrier system on the generation of these subtypes.

271 Another advantage is that the carrier system appears to induce a faster growth rate of T cells given the same
272 IL2 concentration compared to beads (Fig. 3) along with retaining memory phenotype. This has benefits in multiple
273 contexts. Firstly, some patients have small starting T cell populations (such as infants or those who are severely
274 lymphodepleted), and thus require more population doublings to reach a usable dose. Our data suggests the time
275 to reach this dose would be reduced, easing scheduling a reducing cost. Secondly, the allogeneic T cell model would
276 greatly benefit from a system that could create large numbers of T cells with memory phenotype. In contrast to the
277 autologous model which is currently used for *Kymriah* and *Yescarta*, allogeneic T cell therapy would reduce cost by
278 spreading manufacturing expenses across many doses for multiple patients [46]. Since it is economically advantageous
279 to grow as many T cells as possible in one batch in the allogeneic model (reduced start up and harvesting costs,
280 fewer required cell donations), the carriers offer an advantage over current technology.

281 Finally, while we have demonstrated the carrier system in the context of CAR T cells, this method can theoretically
282 be applied to any T cell immunotherapy which responds to anti-CD3/CD28 mAb and cytokine stimulation. These
283 include tumor infiltrating lymphocytes (TILs), virus-specific T cells (VSTs), T cells engineered to express $\gamma\delta$ TCR
284 (TEGs), $\gamma\delta$ T cells, T cells with transduced-TCR, and CAR-TCR T cells [47–52]. Similar to CD19-CARs used
285 in liquid tumors, these T cell immunotherapies would similarly benefit from the increased proliferative capacity,
286 metabolic fitness, migration, and engraftment potential characteristic of memory phenotypes [53–55]. Indeed, since
287 these T cell immunotherapies are activated and expanded with either soluble mAbs or bead-immobilized mAbs, our
288 system will likely serve as a drop-in substitution to provide these benefits.

289 Conclusions

290 In summary, we have developed an *in vivo*-inspired T cell expansion system using porous, degradable, gelatin micro-
291 carriers functionalized with anti-CD3 and anti-CD28 mAbs. Using this system, we have shown that we can achieve
292 higher frequencies of clinically-relevant memory and CD4+ T cell phenotypes compared to traditional bead-based
293 approaches. Additionally, we have shown that they still achieve greater fold change and memory T cell yield beads at
294 low-IL2 concentrations (20 U/mL), and that they can generate functional CAR T cells using lentiviral transduction
295 methods. This system is highly applicable to current T cell manufacturing processes where it may be used to provide
296 higher quality immunotherapies at a reduced reagent cost.

297 **Methods**

298 **Microcarrier Functionalization**

299 Gelatin microcarriers (CuS or CuG, GE Healthcare) were suspended at 20 mg/mL in 1X phosphate buffered saline
300 (PBS) and autoclaved. All subsequent steps were done aseptically, and all reactions were carried out at 20 mg/mL
301 carriers at room temperature under constant agitation. SNB (Thermo Fisher or Apex Bio) was dissolved at 10 μ M in
302 sterile ultrapure water and 7.5 μ L_{SNB}/mL_{PBS} was added to carrier suspension and allowed to react for 60 min. After
303 washing the carriers three times in sterile PBS, 40 μ g/mL STP (Jackson Immunoresearch) was added and allowed
304 to react for 60 min. After the reaction, supernatant was taken for the binding assay, and the carriers were washed
305 twice using sterile PBS. Biotinylated mAbs against human CD3 and CD28 were combined in a 1:1 mass ratio and
306 added to the carriers at 2 μ g_{mAbs}/mg_{carriers}. In the case of the DOE experiment where variable mAb surface density
307 was utilized, the anti-CD3/anti-CD28 mAb mixture was further combined with a biotinylated isotype control to
308 reduce the overall fraction of targeted mAbs (for example the 60% mAb surface density corresponded to 3 mass
309 parts anti-CD3, 3 mass parts anti-CD8, and 4 mass parts isotype control). mAbs were allowed to bind to the carriers
310 for 60 min. All mAbs were low endotoxin azide free (Biolegend custom, LEAF specification). Carriers were washed
311 in sterile PBS and washed once again in the cell culture media to be used for the T cell expansion. The concentration
312 of the final carrier suspension was found by taking a 50 μ L sample, plating in a well, and imaging the entire well.
313 The image was then manually counted to obtain a concentration.

314 **Microcarrier Quality Control Assays**

315 STP and mAb binding to the carriers was quantified indirectly using a bicinchoninic acid assay (BCA) kit (Thermo
316 Fisher) according to the manufacture's instructions, with the exception that the standard curve was made with
317 known concentrations of purified STP or IgG instead of bovine serum albumin (BSA). Absorbance at 592 nm was
318 quantified using a Biotek plate reader.

319 Open biotin binding sites on the carriers after STP coating was quantified indirectly using FITC-biotin (Thermo
320 Fisher). Briefly, 400 pmol/mL FITC-biotin were added to STP-coated carriers and allowed to react for 20 min at
321 room temperature under constant agitation. The supernatant was quantified against a standard curve of FITC-biotin
322 using a Biotek plate reader.

323 **T Cell Culture**

324 Cryopreserved primary human T cells were either obtained as sorted CD3 subpopulations (Astarte Biotech) or
325 isolated from PBMCs (Zenbio) using a negative selection MACS kit for the CD3 subset (Miltenyi Biotech). T cells
326 were activated using carriers or CD3/CD28 magnetic beads (Miltenyi Biotech). In the case of beads, T cells were
327 activated at the manufacturer recommended cell:bead ratio of 2:1. In the case of carriers, cells were activated using

328 2500 carriers/cm² unless otherwise noted. Initial cell density was to 2.0×10^6 cells/mL to 2.5×10^6 cells/mL in a
329 96 well plate with 300 μ L volume. All media was serum-free Cell Therapy Systems OpTmizer (Thermo Fisher) or
330 TexMACS (Miltenyi Biotech) supplemented with 400 U/mL recombinant human IL2 (Peprotech). Cell cultures were
331 expanded for 14 d as counted from the time of initial seeding and activation. Cell counts and viability were assessed
332 using trypan blue or AO/PI and a Countess Automated Cell Counter (Thermo Fisher). Media was added to cultures
333 every 2 d to 3 d depending on media color or a 300 mg/dL minimum glucose threshold. Media glucose was measured
334 using a ChemGlass glucometer.

335 Chemotaxis Assay

336 Migratory function was assayed using a transwell chemotaxis assay as previously described [56]. Briefly, 3×10^5 cells
337 were loaded into a transwell plate (5 μ m pore size, Corning) with the basolateral chamber loaded with 600 μ L media
338 and 0, 250, or 1000 ng/mL CCL21 (Peprotech). The plate was incubated for 4 h after loading, and the basolateral
339 chamber of each transwell was quantified for total cells using countbright beads (Thermo Fisher). The final readout
340 was normalized using the 0 ng/mL concentration as background.

341 Degranulation Assay

342 Cytotoxicity of expanded CAR T cells was assessed using a degranulation assay as previously described [57]. Briefly,
343 3×10^5 T cells were incubated with 1.5×10^5 target cells consisting of either K562 wild type cells (ATCC) or CD19-
344 expressing K562 cells transformed with CRISPR (kindly provided by Dr. Yvonne Chen, UCLA) [58]. Cells were
345 seeded in a flat bottom 96 well plate with 1 μ g/mL anti-CD49d (eBioscience), 2 μ M monensin (eBioscience), and
346 1 μ g/mL anti-CD28 (eBioscience) (all mAbs functional grade) with 250 μ L total volume. After 4 h hour incubation
347 at 37 °C, cells were stained for CD3, CD4, and CD107a and analyzed on a BD LSR Fortessa. Readout was calculated
348 as the percent CD107a+ cells of the total CD8 fraction.

349 CAR Expression

350 CAR expression was quantified as previously described [59]. Briefly, cells were washed once and stained with biotiny-
351 lated Protein L (Thermo Fisher). After a subsequent wash, cells were stained with PE-STP (Biolegend), washed
352 again, and analyzed on a BD Accuri. Readout was percent PE+ cells as compared to secondary controls (PE-STP
353 with no Protein L).

354 CAR Plasmid and Lentiviral Transduction

355 The anti-CD19-CD8-CD137-CD3z chimeric antigen receptor with the EF1 α promotor [28] was synthesized (Alde-
356 vron) and subcloned into a FUGW lentiviral transfer plasmid (Emory Viral Vector Core). Lentiviral vectors were
357 synthesized by the Emory Viral Vector Core or the Cincinnati Children's Hospital Medical Center Viral Vector Core.

358 To transduce primary human T cells, retronectin (Takara) was coated onto non-TC treated 96 well plates and used
359 to immobilize lentiviral vector particles according to the manufacturer’s instructions. Briefly, retronectin solution
360 was adsorbed overnight at 4 °C and blocked the next day using BSA. Prior to transduction, lentiviral supernatant
361 was spinoculated at 2000 ×g for 2 h at 4 °C. T cells were activated in 96 well plates using beads or carriers for 24 h,
362 and then cells and beads/carriers were transferred onto lentiviral vector coated plates and incubated for another
363 24 h. Cells and beads/carriers were removed from the retronectin plates using vigorous pipetting and transferred to
364 another 96 well plate wherein expansion continued.

365 **Statistical Analysis**

366 Statistical significance was evaluated using least-squares linear regression using the *lm* function in R. Stepwise
367 regression models were obtained using the *stepAIC* function from the *MASS* package with forward and reverse
368 stepping. All results with categorical variables are reported relative to baseline reference. Each linear regression
369 was assessed for validity using residual plots (to assess constant variance and independence assumptions), QQ-
370 plots and Shapiro-Wilk normality test (to assess normality assumptions), Box-Cox plots (to assess need for power
371 transformations), and lack-of-fit tests where replicates were present (to assess model fit in the context of pure error).
372 Statistical significance was evaluated at $\alpha = 0.05$.

373 For the DOE analysis, the design matrix was created using JMP 13.1 (SAS) with the custom design tool using
374 I-optimal criterion (to minimize prediction variance) and 4 replicates with 2 center points. The experiment was
375 analyzed using linear regression techniques (as described above).

376 All summary tables were generated using the *stargazer* package in R [60].

377 **Flow Cytometry Antibodies**

378 All mAbs used for flow cytometry are outlined in Table S11.

379 **Symbolic Regression**

380 Symbolic regression was done using Evolved Analytics’ DataModeler software. DataModeler uses genetic program-
381 ming to evolve many symbolic regression models, and then selects the fittest models defined as those with the best
382 trade-off of R^2 (fit) and complexity (this selection accomplished via a pareto front and identifying models at the
383 knee). The collection of fittest models forms a diverse ensemble; the models in the ensemble will agree at observed
384 data points but diverge in extrapolated parameter spaces, providing a trust metric. Feature selection can also be
385 achieved by investigating which variables are present in the fittest models within the ensemble.

386 In this analysis, DataModeler’s SymbolicRegression function was used to develop nonlinear algebraic models. The
387 fittest models were analyzed to identify dominant variables using the VariablePresence and VariableCombinations
388 functions. CreateModelEnsemble was used to define trustable models using selected variable combinations and these

389 were evaluated using the ModelSummaryTable to identify key statistical attributes with prediction and residual
390 performance assessed visually via the EnsemblePredictionPlot and EnsembleResidualPlot functions, respectively.

391 Models were developed targeting Memory and CD4 cells with maxima calculated using the ResponsePlotExplorer
392 function. Trade-off performance between these two attributes were explored using the MultiTargetResponseExplorer
393 and ResponseComparisonExplorer with additional insights derived from the ResponseContourPlotExplorer. Graphics
394 and tables were generated by DataModeler.

395 **Author Contributions**

396 N.J.D., H.W.S., T.K. and K.R. wrote and edited the manuscript. N.J.D., H.W.S, and K.R. designed the experiments.
397 N.J.D. and A.P. optimized the microcarriers and designed the quality control assays. N.J.D. and H.W.S. cultured
398 the T cells and executed the cellular assays. N.J.D. and H.W.S. analyzed the data and generated the figures. T.K.
399 performed symbolic regression. K.R. acquired funding to support the researchers and personnel.

400 **Acknowledgments**

401 This work was supported by the Cell Manufacturing Technologies (CMA_T) National Science Foundation (NSF) Engi-
402 neering Research Center (Grant EEC-1648035), the NSF Early-Concept Grants for Exploratory Research (EAGER)
403 program (grant 1547638), and the Marcus Foundation, the Georgia Research Alliance, and the Georgia Tech Founda-
404 tion through their support of the Marcus Center for Therapeutic Cell Characterization and Manufacturing (MC3M)
405 at Georgia Tech. N.D. was supported by the NSF Graduate Research Fellowships Program and the NSF Integrative
406 Graduate Education and Research Traineeship (IGERT, grant 0965945). H.W.S was supported by the NSF EAGER
407 program (grant 1547638). The authors also acknowledge the Viral Vector Core of the Emory Neuroscience National
408 Institute of Neurological Disorders and Stroke (NINDS) Core Facilities (grant P30NS055077) and the Viral Vector
409 Core at Cincinnati Children’s Hospital Medical Center. The authors also thank Dr. Yvonne Chen and Eugenia Zah
410 (UCLA) for providing the K562-CD19+ tumor cells.

411 **Conflicts of Interest**

412 T.K. is the CEO of Evolved Analytics LLC which produced the DataModeler software package. The remaining
413 authors declare no conflicts of interest.

414 **Acronyms**

415 **ACT** adoptive cell therapies. 1

416 **AIC** Akaike information criteria. 10

417 **AO/PI** acridine orange/propidium iodide. 10, 17

418 **APC** antigen presenting cell. 2

419 **BCA** bicinchoninic acid assay. 17

420 **BSA** bovine serum albumin. 17, 18

421 **CAR** chimeric antigen receptor. 1, 3, 5, 12–14, 16, 18

422 **CHO** Chinese hamster ovary. 2

423 **CuG** Cultispher-G. 3, 4, 16

424 **CuS** Cultispher-S. 3, 4, 16

425 **DC** dendritic cell. 2

426 **DOE** design of experiments. 1, 7, 8, 14–16, 19

427 **ECM** extracellular matrix. 1, 2

428 **GMP** Good Manufacturing Practices. 2

429 **IgG** immunoglobulin G. 3, 4, 17

430 **mAb** monoclonal antibody. 1–4, 7, 10–19

431 **MACS** magnetic activated cell sorting. 5, 17

432 **MHC** major histocompatibility complex. 2

433 **MTT** 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide. 3

434 **PBMC** peripheral blood mononuclear cell. 5, 17

435 **PBS** phosphate buffered saline. 16

436 **PDMS** polydimethylsiloxane. 2

437 **SNB** sulfo-NHS-biotin. 3, 4, 16

438 **STP** streptavidin. 3, 4, 16–18

439 **TCR** T Cell Receptor. 14, 16

440 **TEG** T cell engineered to express $\gamma\delta$ TCR. 16

441 **TIL** tumor infiltrating lymphocyte. 16

442 **VST** virus-specific T cell. 16

443 References

- 444 [1] Fesnak, A. D., June, C. H. & Levine, B. L. Engineered t cells: the promise and challenges of cancer immunother-
445 apy. *Nature Reviews Cancer* **16**, 566–581 (2016).
- 446 [2] Rosenberg, S. A. & Restifo, N. P. Adoptive cell transfer as personalized immunotherapy for human cancer.
447 *Science* **348**, 62–68 (2015).
- 448 [3] Roddie, C., O'Reilly, M., Pinto, J. D. A., Vispute, K. & Lowdell, M. Manufacturing chimeric antigen receptor
449 t cells: issues and challenges. *Cytotherapy* (2019).
- 450 [4] Dwarshuis, N. J., Parratt, K., Santiago-Miranda, A. & Roy, K. Cells as advanced therapeutics: State-of-the-art,
451 challenges, and opportunities in large scale biomanufacturing of high-quality cells for adoptive immunotherapies.
452 *Advanced Drug Delivery Reviews* **114**, 222–239 (2017).
- 453 [5] Wang, X. & Rivière, I. Clinical manufacturing of CAR t cells: foundation of a promising therapy. *Molecular*
454 *Therapy - Oncolytics* **3**, 16015 (2016).
- 455 [6] Piscopo, N. J. *et al.* Bioengineering solutions for manufacturing challenges in CAR t cells. *Biotechnology Journal*
456 **13**, 1700095 (2017).
- 457 [7] Bashour, K. T. *et al.* Functional characterization of a t cell stimulation reagent for the production of therapeutic
458 chimeric antigen receptor t cells. *Blood* **126**, 1901–1901 (2015).
- 459 [8] Gendron, S., Couture, J. & Aoudjit, F. Integrin $\alpha 2\beta 1$ inhibits fas-mediated apoptosis in t lymphocytes by
460 protein phosphatase 2a-dependent activation of the MAPK/ERK pathway. *Journal of Biological Chemistry*
461 **278**, 48633–48643 (2003).
- 462 [9] Ohtani, O. & Ohtani, Y. Structure and function of rat lymph nodes. *Archives of Histology and Cytology* **71**,
463 69–76 (2008).
- 464 [10] Boisvert, M., Gendron, S., Chetoui, N. & Aoudjit, F. Alpha2beta1 integrin signaling augments t cell receptor-
465 dependent production of interferon-gamma in human t cells. *Molecular Immunology* **44**, 3732–3740 (2007).

- 466 [11] Ben-Horin, S. & Bank, I. The role of very late antigen-1 in immune-mediated inflammation. *Clinical Immunology*
467 **113**, 119–129 (2004).
- 468 [12] Forget, M.-A. *et al.* Activation and propagation of tumor-infiltrating lymphocytes on clinical-grade designer
469 artificial antigen-presenting cells for adoptive immunotherapy of melanoma. *Journal of Immunotherapy* **37**,
470 448–460 (2014).
- 471 [13] Cheung, A. S., Zhang, D. K. Y., Koshy, S. T. & Mooney, D. J. Scaffolds that mimic antigen-presenting cells
472 enable ex vivo expansion of primary T cells. *Nature Biotechnology* **36**, 160–169 (2018).
- 473 [14] del Río, E. P., Miguel, M. M., Veciana, J., Ratera, I. & Guasch, J. Artificial 3d culture systems for t cell
474 expansion. *ACS Omega* **3**, 5273–5280 (2018).
- 475 [15] Delalat, B. *et al.* 3D printed lattices as an activation and expansion platform for T cell therapy. *Biomaterials*
476 **140**, 58–68 (2017).
- 477 [16] Meyer, R. A. *et al.* Immunoengineering: Biodegradable nanoellipsoidal artificial antigen presenting cells for
478 antigen specific t-cell activation (small 13/2015). *Small* **11**, 1612–1612 (2015).
- 479 [17] Lambert, L. H. *et al.* Improving T Cell Expansion with a Soft Touch. *Nano letters* **17**, 821–826 (2017).
- 480 [18] Xu, Y. *et al.* Closely related t-memory stem cells correlate with in vivo expansion of car.cd19-t cells and are
481 preserved by il-7 and il-15. *Blood* **123**, 3750–3759 (2014).
- 482 [19] Gattinoni, L., Klebanoff, C. A. & Restifo, N. P. Paths to stemness: building the ultimate antitumour T cell.
483 *Nature reviews. Cancer* **12**, 671–84 (2012).
- 484 [20] Fraietta, J. A. *et al.* Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) t cell
485 therapy of chronic lymphocytic leukemia. *Nature Medicine* **24**, 563–571 (2018).
- 486 [21] Gattinoni, L. *et al.* A human memory t cell subset with stem cell-like properties. *Nature Medicine* **17**, 1290–1297
487 (2011).
- 488 [22] Wang, D. *et al.* Glioblastoma-targeted CD4+ CAR t cells mediate superior antitumor activity. *JCI Insight* **3**
489 (2018).
- 490 [23] Yang, Y. *et al.* TCR engagement negatively affects CD8 but not CD4 CAR t cell expansion and leukemic
491 clearance. *Science Translational Medicine* **9**, eaag1209 (2017).
- 492 [24] Heathman, T. R. J. *et al.* Expansion, harvest and cryopreservation of human mesenchymal stem cells in a
493 serum-free microcarrier process. *Biotechnology and Bioengineering* **112**, 1696–1707 (2015).
- 494 [25] Sart, S., Errachid, A., Schneider, Y.-J. & Agathos, S. N. Controlled expansion and differentiation of mesenchymal
495 stem cells in a microcarrier based stirred bioreactor. *BMC Proceedings* **5** (2011).

- 496 [26] Tumaini, B. *et al.* Simplified process for the production of anti-CD19-CAR-engineered T cells. *Cytotherapy* **15**,
497 1406–15 (2013).
- 498 [27] Lamers, C. H. J. *et al.* T cell receptor-engineered T cells to treat solid tumors: T cell processing toward optimal
499 T cell fitness. *Human gene therapy methods* **25**, 345–57 (2014).
- 500 [28] Milone, M. C. *et al.* Chimeric receptors containing CD137 signal transduction domains mediate enhanced
501 survival of t cells and increased antileukemic efficacy in vivo. *Molecular Therapy* **17**, 1453–1464 (2009).
- 502 [29] Ghassemi, S. *et al.* Reducing Ex Vivo Culture improves the antileukemic activity of chimeric antigen receptor
503 (CAR) t cells. *Cancer Immunology Research* **6**, 1100–1109 (2018).
- 504 [30] Matic, J., Deeg, J., Scheffold, A., Goldstein, I. & Spatz, J. P. Fine tuning and efficient T cell activation with
505 stimulatory aCD3 nanoarrays. *Nano letters* **13**, 5090–7 (2013).
- 506 [31] Joshi, N. S. & Kaech, S. M. Effector CD8 t cell development: A balancing act between memory cell potential
507 and terminal differentiation. *The Journal of Immunology* **180**, 1309–1315 (2008).
- 508 [32] Adachi, K. *et al.* IL-7 and CCL19 expression in CAR-t cells improves immune cell infiltration and CAR-t cell
509 survival in the tumor. *Nature Biotechnology* **36**, 346–351 (2018).
- 510 [33] Rosenberg, S. A. *et al.* Durable complete responses in heavily pretreated patients with metastatic melanoma
511 using t-cell transfer immunotherapy. *Clinical Cancer Research* **17**, 4550–4557 (2011).
- 512 [34] Besser, M. J. *et al.* Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor
513 infiltration lymphocytes in metastatic melanoma patients. *Clinical Cancer Research* **16**, 2646–2655 (2010).
- 514 [35] Kalos, M. *et al.* T cells with chimeric antigen receptors have potent antitumor effects and can establish memory
515 in patients with advanced leukemia. *Science translational medicine* **3**, 95ra73 (2011).
- 516 [36] Sommermeyer, D. *et al.* Chimeric antigen receptor-modified t cells derived from defined CD8+ and CD4+
517 subsets confer superior antitumor reactivity in vivo. *Leukemia* **30**, 492–500 (2015).
- 518 [37] Rao, W. H., Hales, J. M. & Camp, R. D. R. Potent costimulation of effector t lymphocytes by human collagen
519 type i. *The Journal of Immunology* **165**, 4935–4940 (2000).
- 520 [38] Bank, I., Book, M. & Ware, R. Functional role of VLA-1 (CD49a) in adhesion, cation-dependent spreading, and
521 activation of cultured human t lymphocytes. *Cellular Immunology* **156**, 424–437 (1994).
- 522 [39] Hickey, J. W., Vicente, F. P., Howard, G. P., Mao, H.-Q. & Schneck, J. P. Biologically inspired design of
523 nanoparticle artificial antigen-presenting cells for immunomodulation. *Nano Letters* **17**, 7045–7054 (2017).
- 524 [40] Gomez-Eerland, R. *et al.* Manufacture of gene-modified human t-cells with a memory stem/central memory
525 phenotype. *Human Gene Therapy Methods* **25**, 277–287 (2014).

- 526 [41] Buck, M. D. *et al.* Mitochondrial Dynamics Controls T Cell Fate through Metabolic Programming. *Cell* **166**,
527 114 (2016).
- 528 [42] van der Windt, G. J. *et al.* Mitochondrial respiratory capacity is a critical regulator of CD8+ t cell memory
529 development. *Immunity* **36**, 68–78 (2012).
- 530 [43] D'Souza, W. N. & Hedrick, S. M. Cutting edge: Latecomer CD8 t cells are imprinted with a unique differentiation
531 program. *The Journal of Immunology* **177**, 777–781 (2006).
- 532 [44] Gerdemann, U., Vera, J. F., Rooney, C. M. & Leen, A. M. Generation of multivirus-specific T cells to pre-
533 vent/treat viral infections after allogeneic hematopoietic stem cell transplant. *Journal of visualized experiments*
534 : *JoVE* (2011).
- 535 [45] Jin, J. *et al.* Simplified method of the growth of human tumor infiltrating lymphocytes in gas-permeable flasks
536 to numbers needed for patient treatment. *Journal of immunotherapy (Hagerstown, Md. : 1997)* **35**, 283–92
537 (2012).
- 538 [46] Harrison, R. P., Zylberberg, E., Ellison, S. & Levine, B. L. Chimeric antigen receptor–t cell therapy manufac-
539 turing: modelling the effect of offshore production on aggregate cost of goods. *Cytotherapy* (2019).
- 540 [47] Cho, H.-W. *et al.* Triple costimulation via CD80, 4-1bb, and CD83 ligand elicits the long-term growth of $\nu\gamma 9\nu\delta 2$
541 t cells in low levels of IL-2. *Journal of Leukocyte Biology* **99**, 521–529 (2015).
- 542 [48] Straetemans, T. *et al.* GMP-grade manufacturing of t cells engineered to express a defined $\gamma\delta$ TCR. *Frontiers*
543 *in Immunology* **9** (2018).
- 544 [49] Robbins, P. F. *et al.* Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using
545 genetically engineered lymphocytes reactive with NY-ESO-1. *Journal of Clinical Oncology* **29**, 917–924 (2011).
- 546 [50] Brimnes, M. K. *et al.* Generation of autologous tumor-specific t cells for adoptive transfer based on vaccination,
547 in vitro restimulation and CD3/CD28 dynabead-induced t cell expansion. *Cancer Immunology, Immunotherapy*
548 **61**, 1221–1231 (2012).
- 549 [51] Baldan, V., Griffiths, R., Hawkins, R. E. & Gilham, D. E. Efficient and reproducible generation of tumour-
550 infiltrating lymphocytes for renal cell carcinoma. *British Journal of Cancer* **112**, 1510–1518 (2015).
- 551 [52] Walseng, E. *et al.* A TCR-based chimeric antigen receptor. *Scientific Reports* **7** (2017).
- 552 [53] Blanc, C. *et al.* Targeting resident memory t cells for cancer immunotherapy. *Frontiers in Immunology* **9** (2018).
- 553 [54] Lalor, S. J. & McLoughlin, R. M. Memory $\gamma\delta$ t cells—newly appreciated protagonists in infection and immunity.
554 *Trends in Immunology* **37**, 690–702 (2016).

- 555 [55] Rosato, P. C. *et al.* Virus-specific memory t cells populate tumors and can be repurposed for tumor immunother-
556 apy. *Nature Communications* **10** (2019).
- 557 [56] Hromas, R. *et al.* Cloning and characterization of exodus, a novel beta-chemokine. *Blood* **89**, 3315–3322 (1997).
- 558 [57] Schmoldt, A., Benthe, H. F. & Haberland, G. Digitoxin metabolism by rat liver microsomes. *Biochemical*
559 *pharmacology* **24**, 1639–1641 (1975).
- 560 [58] Zah, E., Lin, M.-Y., Silva-Benedict, A., Jensen, M. C. & Chen, Y. Y. T cells expressing cd19/cd20 bispecific
561 chimeric antigen receptors prevent antigen escape by malignant b cells. *Cancer immunology research* **4**, 498–508
562 (2016).
- 563 [59] Zheng, Z., Chinnasamy, N. & Morgan, R. A. Protein l: a novel reagent for the detection of chimeric antigen
564 receptor (CAR) expression by flow cytometry. *Journal of Translational Medicine* **10**, 29 (2012).
- 565 [60] Hlavac, M. *stargazer: Well-Formatted Regression and Summary Statistics Tables*. Central European Labour
566 Studies Institute (CELSI), Bratislava, Slovakia (2018). R package version 5.2.2.